Comparative Pharmacology
Head-to-head clinical analysis: MENRIUM 5 4 versus PAXIPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MENRIUM 5 4 versus PAXIPAM.
MENRIUM 5-4 vs PAXIPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an anticholinergic that blocks muscarinic acetylcholine receptors.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
1 tablet (chlordiazepoxide 5 mg / clinidium bromide 2.5 mg) orally 3 to 4 times daily before meals and at bedtime. Maximum dose: 8 tablets per day.
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
None Documented
None Documented
Chlordiazepoxide: Terminal half-life 5-30 hours (mean 10 hours), extended to 30-60 hours in elderly or hepatic impairment. Clidinium: Terminal half-life approximately 1-2 hours due to rapid clearance.
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Chlordiazepoxide: Renal excretion of unchanged drug (<1%) and conjugates (60-70%); fecal excretion (30-40%). Clidinium: Primarily renal elimination as unchanged drug and metabolites (50-70%), with biliary/fecal excretion (30-50%).
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Category C
Category C
Benzodiazepine/Estrogen Combination
Benzodiazepine